Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
25.76M | 26.18M | 28.21M | 21.28M | 17.31M | Gross Profit |
9.89M | 9.77M | 9.98M | 7.21M | 5.87M | EBIT |
863.71K | 460.15K | -1.10M | 3.89M | 1.81M | EBITDA |
2.50M | 994.47K | 420.35K | 4.76M | 2.36M | Net Income Common Stockholders |
1.38M | -1.05M | -835.75K | 1.76M | 1.26M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.40M | 894.76K | 1.27M | 1.73M | 2.78M | Total Assets |
22.39M | 20.90M | 23.95M | 26.77M | 17.54M | Total Debt |
2.53M | 1.40M | 3.97M | 6.20M | 5.96M | Net Debt |
1.12M | 503.65K | 2.69M | 4.47M | 3.18M | Total Liabilities |
4.14M | 2.70M | 5.27M | 8.29M | 7.69M | Stockholders Equity |
18.25M | 18.20M | 18.68M | 18.48M | 9.84M |
Cash Flow | Free Cash Flow | |||
1.36M | 2.13M | 949.49K | 2.18M | 3.01M | Operating Cash Flow |
1.39M | 2.15M | 1.02M | 2.18M | 3.01M | Investing Cash Flow |
-1.59M | -23.13K | -56.24K | -7.40M | -1.56M | Financing Cash Flow |
729.78K | -2.52M | -1.41M | 4.33M | -325.46K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | C$23.57M | 20.45 | 4.53% | ― | 4.09% | ― | |
65 Neutral | C$186.31M | ― | -4.48% | ― | -0.69% | 8.08% | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
C$13.86M | ― | ― | ― | ― | |||
$150.51K | ― | ― | ― | ― | |||
$189.99M | ― | ― | ― | ― | |||
54 Neutral | C$3.89M | ― | -239.50% | ― | 3.03% | -410.90% |
Nova Leap Health Corp announced that all items of business were approved at their annual and special meeting of shareholders, including the election of six board members and the re-appointment of their auditor. Additionally, the company’s 10% rolling equity incentive plan was ratified, reflecting strong shareholder support and potentially impacting the company’s strategic initiatives and stakeholder interests.
The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.60 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.
Nova Leap Health Corp. reported a 7.7% increase in Q1 2025 revenues compared to Q4 2024, although Adjusted EBITDA decreased by 30%. The company made strategic acquisitions in Nova Scotia, contributing to its fastest-growing segment, and opened a new office in Kentucky. Despite a net loss in Q1, the company expects record revenues in Q2, driven by recent investments and acquisitions.
Nova Leap Health Corp. has completed the acquisition of a home care services company in Nova Scotia for $390,000, funded with cash on hand. This acquisition is part of Nova Leap’s strategy to expand its market presence in Nova Scotia, enhancing its operations and potentially benefiting stakeholders by increasing its service capacity in the region.